largazole and Central-Nervous-System-Diseases

Largazole is a potent class I selective histone deacetylase inhibitor prodrug with anticancer activity against solid tumors in preclinical models. Largazole possesses in vitro activity against glioblastoma multiforme (GBM) cells and sufficiently crosses the blood-brain barrier based on measurement of the active species, largazole thiol, to achieve therapeutically relevant concentrations in the mouse brain. The effective dose resulted in pronounced functional responses on the transcript level based on RNA sequencing and quantitative polymerase chain reaction after reverse transcription (RT-qPCR), revealing desirable expression changes of genes related to neuroprotection, including

Topics: Animals; Brain; Cell Line, Tumor; Central Nervous System Diseases; Depsipeptides; Glioblastoma; Histone Deacetylase Inhibitors; Mice; Thiazoles